Antineoplastics
1
Reactions 656 - 21 Jun 1997 Paroxetine ‘Shock-like’ paraesthesias: 3 case reports Three women experienced transient, paroxysmal shock-like paraesthesias after they started treatment with paroxetine 20 mg/day for depression. The first patient, aged 25 years, developed facial paraesthesias for the first 3 days of treatment, shortly after she took paroxetine. Each episode lasted for approximately 5 minutes, but did not recur after the third day of paroxetine therapy. The second patient, aged 29 years, experienced symptoms, similar to an electric shock, repeatedly over a 3-minute period on the second day of treatment with paroxetine. She discontinued the medication and was subsequently treated with sertraline with no adverse effects. For the first 5 days of therapy, after her morning dose of paroxetine, the third patient, aged 22 years, had a paroxysm of electric shock-like paraesthesias in her head, which lasted approximately 15 seconds. The symptoms then resolved and the woman continued paroxetine treatment with no further adverse effects. Berigan TR, et al. Transient, paroxysmal, shock-like paresthesias associated with paroxetine initiation. Journal of Clinical Psychiatry 58: 175-176, Apr 1997 - USA 800535350 1 Reactions 21 Jun 1997 No. 656 0114-9954/10/0656-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1420 - 22 Sep 2012
SAntineoplastics
Neutropenia and thrombocytopenia in a neonate:case report
A 16-day-old boy with a congenital Askin tumourdeveloped haematological toxicities during chemotherapy[routes, dosages, durations of treatment to reactions onsetand outcomes not stated].
The tumour had been diagnosed at 37 weeks’ gestation.The baby was born at term via Caesarean delivery,weighing 3.390kg. Following complete gross resection ofthe lesion, he received isofosamide, carboplatin, etoposide,cyclophosphamide, doxorubicin and vincristine (ICE-CAV).Doses were adjusted for age and weight considering asquare metre equivalent to 30kg and a further dosereduction of 25–30% for a weight less than 5kg. Duringchemotherapy, he developed grade 3/4 neutropenia and/orthrombocytopenia. He achieved complete remission andwas disease-free at last follow-up.
Author comment: "[T]he ICE-CAV regimen that wasadministered with the chemotherapy dose adjusted forweight was well tolerated with manageable short- and long-term toxicities."Crocoli A, et al. Congenital Askin tumor with favorable outcome: Case report andreview of the literature. Journal of Pediatric Surgery 47: 1440-1444, No. 7, Jul2012. Available from: URL: http://dx.doi.org/10.1016/j.jpedsurg.2012.02.028 -Italy 803077388
1
Reactions 22 Sep 2012 No. 14200114-9954/10/1420-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
